Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Generic Drugs Value-Added Medicines

What’s Next? Five Things To Look Out For In August

US Vyvanse Exclusivity To Dominate Headlines This Month

  • Analysis

Executive Summary

Generics Bulletin previews the most notable and anticipated events for August 2023.

You may also be interested in...



Norwich Loses US Vyvanse Appeal – But Patents Run Course In August

US-based Norwich Pharmaceuticals has lost its bid to move several months early on US competition to Takeda’s Vyvanse ADHD blockbuster.

Vanda Lodges ANDA Trade Secret Case Against US Government

US originator Vanda Pharmaceutical namechecked several generics manufacturers, including Teva, as part of its trade secrets and confidential information lawsuit against the US government.

Sandoz, Accord Confirm First US Aubagio Generics, As Settlement Day Arrives

Viatris’ Mylan and Teva are among firms holding approved ANDAs for generic Aubagio, as the product falls to generic competition in the US.

Table

View full table

Related Content

Generics Bulletin

Topics

Tags:
Biosimilars Generic Drugs Value-Added Medicines
Latest Headlines

Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’

Not In 2023 After All? FDA Turns Down Approval For Coherus’ On-Body Pegfilgrastim

Sandoz Prepares For European Natalizumab Launch As Approval Arrives

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

See All
UsernamePublicRestriction

Register

GB152884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By